TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Rating of “Buy” from Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have received a consensus rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.08.

A number of research analysts recently issued reports on TLSI shares. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Mkm began coverage on shares of TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 target price on the stock. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Finally, Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 target price for the company.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $4.32 on Wednesday. The company has a fifty day moving average of $4.24 and a two-hundred day moving average of $5.49. TriSalus Life Sciences has a 1 year low of $3.61 and a 1 year high of $10.42. The company has a market capitalization of $131.73 million, a PE ratio of -1.73 and a beta of 0.49.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela purchased 7,520 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the purchase, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 2.03 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 19,560 shares of company stock worth $95,190 over the last ninety days. 32.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently made changes to their positions in the stock. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the second quarter valued at about $1,184,000. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at approximately $240,000. Duquesne Family Office LLC boosted its stake in shares of TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares during the period. Finally, Virtu Financial LLC purchased a new position in TriSalus Life Sciences in the 3rd quarter valued at approximately $92,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.